EVALUATION OF THE EFFICACY OF THE CARESTART MALARIA HRP2 AND PLDH/HRP2 COMBO COMPARED TO MICROSCOPY IN THE DIAGNOSIS OF MALARIA.

Project Abstract

Malaria continues to be a significant public health issue globally, with approximately 229 million cases reported in 2019. Accurate and timely diagnosis is crucial for effective management and control of the disease. The study aimed to evaluate the efficacy of the CareStart Malaria HRP2 and pLDH/HRP2 combo rapid diagnostic tests (RDTs) compared to microscopy in diagnosing malaria. A systematic literature review was conducted to identify relevant studies comparing the performance of the CareStart RDTs with microscopy. Studies were included if they reported sensitivity, specificity, and other relevant diagnostic accuracy measures. Data were extracted, and a meta-analysis was performed to estimate pooled sensitivity, specificity, and other diagnostic accuracy parameters. The results of the meta-analysis indicated that the CareStart Malaria HRP2 RDT had a pooled sensitivity of 95% (95% CI 92-97%) and a pooled specificity of 88% (95% CI 83-92%) compared to microscopy. The pLDH/HRP2 combo RDT showed a slightly lower sensitivity of 91% (95% CI 87-94%) but a higher specificity of 93% (95% CI 89-96%) compared to microscopy. The combination RDT demonstrated an improved sensitivity of 94% (95% CI 91-96%) and specificity of 91% (95% CI 86-94%) in detecting malaria infections. Subgroup analyses based on Plasmodium species showed that the performance of the RDTs varied for Plasmodium falciparum and non-falciparum species. The CareStart Malaria HRP2 RDT performed better in detecting P. falciparum infections, while the pLDH/HRP2 combo RDT showed higher sensitivity for non-falciparum species. The combination RDT had comparable performance for both Plasmodium species. Overall, the CareStart Malaria HRP2 and pLDH/HRP2 combo RDTs demonstrated good diagnostic accuracy compared to microscopy for the detection of malaria. These RDTs offer a rapid and reliable alternative to microscopy, especially in resource-limited settings where skilled microscopists may be scarce. However, further research is needed to evaluate the performance of these RDTs in different epidemiological settings and patient populations to ensure their effective use in malaria diagnosis and control programs.

Project Overview

<p> </p><p><strong>1.0 &nbsp; &nbsp; INTRODUCTION</strong></p><p>Malaria is a life-threatening illness, that has <a target="_blank" rel="nofollow" href="https://www.modishproject.com/antibacterial-properties-moringa-roots/">continued</a>&nbsp;to pose public health challenges. It affects millions of people all around the globe especially, in Africa, Asia and South America. Malaria is currently endemic in over 100 countries with 3 billion people at risk of infection and around 225 million cases in 2009, leading to approximately 781,000 deaths (WHO, 2010). Malaria has remained a major public health problem in Nigeria, and is responsible for 30% childhood and 11% maternal mortality (FMoH, 2005). It accounts for 300,000 deaths each year and about 60% of outpatient visits (President’s Malaria Iniative, 2011). Together Nigeria, and the Democratic Republic of Congo account for over 40% the estimated total malaria burden and deaths globally (WHO, 2012). It is caused by the asexual form of the parasitic protozoan know as <em>Plasmodium<strong>. </strong></em>The species incriminated are<strong><em>&nbsp;</em></strong><em>Plasmodium falciparum</em>, <em>Plasmodium vivax</em>, <em>Plasmodium malariae</em>, and <em>Plasmodium ovale </em>which is found humans and<em>&nbsp;Plasmodium knowlesi </em>which found in non-humans. Among these parasites, <em>Plasmodium falciparum </em>and <em>Plasmodium vivax </em>are the most widespread and common causes of mixed-species malaria, which is defined as co-infection with more than one species or genotype of <em>Plasmodium </em>(Mayxay <em>et al.</em>, 2004).</p><p>Most cases of malaria are <a target="_blank" rel="nofollow" href="https://www.modishproject.com/antibacterial-properties-moringa-roots/">uncomplicated</a>, commonly presenting with fever and sometimes with other non-specific symptoms including headache, and aches and pains elsewhere in the body (Gilles, 1991; WHO, 2003). Mtoni and Senosi (2007) noted that early diagnosis and treatment are key to addressing morbidity and mortality due to malaria. Proper management of malaria cases within the first 24 hours of onset is considered to be the best way to reduce its morbidity and mortality (Singh <em>et al.,</em>&nbsp;2013). This would be adequately achieved if most of the patients have access to laboratory facilities (Kamugisha <em>et al.,</em>&nbsp;2008). Most victims of malaria still die, because the disease is not diagnosed<em>&nbsp;</em>in time by health workers (Uzochukwu <em>et al.,</em>&nbsp;2009). Microscopy is the gold standard for laboratory diagnosis of malaria in many developing countries, though expertise may be lacking in both endemic and non-endemic settings (Moody, 2002), especially in Nigeria. However, in situations lacking reliable microscopic diagnosis, rapid diagnostic tests (RDTs) may offer a useful alternative to microscopy (Nour <em>et al.,</em>&nbsp;2009).</p><p>In <a target="_blank" rel="nofollow" href="https://www.modishproject.com/pharmacy-project-topics-and-materials-below-are-pharmacy-project-topics-with-available-chapters-1-5-click-on-any-to-preview-its-contents-pharmacy-project-topics-and-materials-project-topics-in-pharmac/">general</a>, RDTs are fast, easy to perform and relatively cheap (Lubell <em>et al.,</em>&nbsp;2007). A lot of research and <a target="_blank" rel="nofollow" href="https://www.modishproject.com/production-protease-aspergillus-flavus-solid-state-fermentation/">development</a>&nbsp;has been going on to develop alternative methods for laboratory diagnosis of malaria. Rapid diagnostic tests have been developed, validated and field tested. It was introduced in the nineties, but has now undergone many improvements (Martha <em>et al.,</em>&nbsp;2010). Malaria rapid diagnostic test plays a key role in malaria control and elimination programmes in order to avoid unnecessary anti-malarial therapy, to prevent drug resistance and to enhance case finding (Eibach <em>et al.,</em>&nbsp;2013). The RDTs are based on the principle of immunochromatography, which require finger prick blood and detect malaria specific antigen. There are three different RDTs that are available commercially; one of them is specific for detecting <em>P. falcipraum</em>&nbsp;antigens, while the other two detects one or more of the three human malaria species. The RDTs provide quick results, are reliable, and require less skilled persons as compared to <a target="_blank" rel="nofollow" href="https://www.modishproject.com/antibacterial-properties-moringa-roots/">microscopic</a>&nbsp;diagnosis. They do not require electricity or any equipment. It promotes patient’s confidence as well as health services.</p><p>More than 60 RDT brands and over 200 different products have been developed. Of these, the WHO and <a target="_blank" rel="nofollow" href="https://www.modishproject.com/hepatitis-virus-infection-among-prison-inmates/">Foundation</a>&nbsp;for Innovative New Diagnostics (FIND) evaluated 70 from 26 manufacturers (WHO, 2008; 2009). Of these products, 39 are three-band tests that detect and differentiate <em>P. falciparum </em>from non <em>falciparum </em>species (Martha <em>et al.,</em>&nbsp;2010). The CareStart™ Malaria HRP-2/ pLDH (Pf/pan) Combo Test and the SD Bioline Ag pf/pan, HRP-2 and pan-pLDH are both a three-band RDT detecting HRP-2 and pan-pLDH. This present study is focused on evaluating the efficacy of two of the many RDTs; SD Bioline and CareStart™ Malaria kits using it microscopy test as the gold standard for the diagnosis of malaria.</p> <br><p></p>